Skip to main content
Matthew Cooperberg, MD, Urology, San Francisco, CA

MatthewRCooperbergMDMPH, FACS

Urology • San Francisco, CA

Surgical Oncology

Helen Diller Family Professor, Department of Urology, UCSF

Join to view full profile

Dr. Cooperberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Cooperberg's full profile

Already have an account?

  • Office

    1825 4th St
    San Francisco, CA 94143
    Phone+1 415-476-4616
    Fax+1 415-514-6195

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Urology, 2002 - 2008
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterInternship, Transitional Year, 2000 - 2001
  • Yale School of Medicine
    Yale School of MedicineClass of 2000

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - 2026
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US  
    Peter E Lonergan, Matthew R Cooperberg, JAMA Network Open
  • Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the Internationa...  
    Michael J Zelefsky, Matthew R Cooperberg, Brian J Davis, Eric M Horwitz, Martha K Terris, Christopher L Amling, Christopher J Kane, Curtiland Deville, Theodore L Dewee..., JAMA Oncology
  • Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability  
    Matthew R Cooperberg, Atreya Dash, JAMA Oncology
  • Join now to see all

Authored Content

  • Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityAugust 2020
  • The Diverse Genomic Landscape of Clinically Low-Risk Prostate CancerMay 2018
  • A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous CohortsMay 2018
  • Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study ResultsFebruary 2018
  • How Should a Man with Prostate Cancer Choose His Surgeon?February 2018
  • Join now to see all

Press Mentions

  • Why Some Prostate Cancers Shouldn’t Be Called ‘Cancer’
    Why Some Prostate Cancers Shouldn’t Be Called ‘Cancer’October 29th, 2024
  • Should We Use the C-word for Mild Prostate Cancer?
    Should We Use the C-word for Mild Prostate Cancer?September 30th, 2024
  • Powerful New Mini Microscopic Will Enable Precision Cancer Surgery
    Powerful New Mini Microscopic Will Enable Precision Cancer SurgeryAugust 21st, 2024
  • Join now to see all

Professional Memberships

Dr. Matthew Cooperberg, Dr. Matthew Cooperberg, MD, Dr. M Cooperberg, Dr. Matthew R Cooperberg